The presentation of ongoing preclinical studies of Narazaciclib at a significant conference increases the visibility of Onconova Therapeutics' work and could potentially attract more investors, positively impacting the stock performance. However, as the studies are still preclinical, the actual impact on the company's revenue and stock price will depend on the results of these studies and the subsequent steps towards commercialization.